CardioSignal and academic research partners present new data demonstrating point-of-care detection capability in heart failure
Data presented at the Heart Failure Society of America Annual Scientific Meeting (HFSA)
With results that compare well with existing clinical methods, this study demonstrates the value of using motion sensor technology, available in most commercial smartphones today, for the detection of clinical heart failure. The multi-site study was conducted at three hospitals, including Stanford University Hospital, Turku University Hospital, and Helsinki University Hospital.
For patients with heart failure, early identification and monitoring are critical to improving outcomes. To address the challenge of delayed diagnosis, the aim of this proof-of-concept study was to determine whether algorithms based on gyroscope and accelerometer motion sensor signals can detect clinical heart failure. The technology is particularly useful for high-risk populations in alleviating the overall health care burden.
The study found motion sensors to be capable of detecting heart failure with an accuracy of over 88%. The sensitivity associated with a clinical diagnosis of HF was 95% while the specificity was 87.9%. The method was found to be capable in detecting both reduced (HFrEF) and preserved (HFpEF) ejection fraction in heart failure.
“For years, we have collaborated closely with physicians and researchers to develop a noninvasive digital cardiac biomarker that could work in earlier detection of heart failure in a primary care setting and in home monitoring. I am excited about these results because, without compromising precision, they can address a major unmet clinical need in timely diagnostics and accessibility of digital health technology in risk populations,” said cardiologist and CEO Juuso Blomster.
Using a commercially available smartphone placed on the patient’s chest, the technology enables a remote care model where only a one-minute measurement is needed to assess myocardial function.
Study details:
Title: Recognition of Heart Failure with Micro Electro-mechanical Sensors (REFLECS)
Presented at the Heart Failure Society of America Scientific Meeting (HFSA)
Presenter: Clinical Professor Francois Haddad, the Stanford University Division of Cardiovascular Medicine
The analysis included over 1000 patients, a total 227 individuals with HF and 848 controls. Patients with either reduced (HFrEF) and preserved (HFpEF) ejection fraction were included
Study was conducted in 2019-2022 at the Stanford University, Turku University Hospital, and Helsinki University Hospital
Further information
CEO Juuso Blomster, juuso.blomster@cardiosignal.com
Communications director Juulia Simonen, juulia.simonen@cardiosignal.com
About CardioSignal
We develop groundbreaking solutions for the detection of heart diseases with digital cardiac biomarkers. CardioSignal utilizes motion sensor technology to non-invasively measure cardiac motion and function. Originally an academic spinoff, the company’s patented technology is built on a decade of research and algorithm development. CardioSignal is a brand and a product by Precordior, a health technology company based in Finland and United States.
